Xvivo Perfusion AB (publ) (STO:XVIVO)

Sweden · Delayed Price · Currency is SEK

191.00

-2.70 (-1.39%)

At close: Feb 10, 2026

Revenue by Product

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Thoracic	384.36M
Thoracic Growth	29.70%
Abdominal	134.04M
Abdominal Growth	89.16%
Services	79.14M
Services Growth	64.61%

Revenue by Geography

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
United States	308.10M
United States Growth	37.01%
EMEA Excluding Sweden, Netherlands and Italy	128.28M
EMEA Excluding Sweden, Netherlands and Italy Growth	32.27%
Italy	58.93M
Italy Growth	174.32%
Asia/Pacific and Oceania	42.18M
Asia/Pacific and Oceania Growth	124.24%
Netherlands	30.22M
Netherlands Growth	16.29%
North and South America, Excluding the United States	25.62M
North and South America, Excluding the United States Growth	0.53%
Sweden	4.22M
Sweden Growth	152.57%